France: Warburg Pincus takes 45% stake in Polyplus

Denis Ribon, chairman, ArchiMed

Warburg Pincus has taken a 45% stake in Archimed-owned Polyplus, a developer of gene and cell therapy technologies. Financial terms have not been disclosed, though the business is understood to be valued at more than US$500m. ArchiMed and Warburg Pincus will now hold 45% stakes each while Polyplus’ management team will hold the remaining 10%….

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »